Genetic and epigenetic analysis of the TIMP-3 gene in ovarian cancer

Cancer Letters
Mira C P LiuIan G Campbell

Abstract

Chromosome 22q shows a high frequency of loss of heterozygosity (LOH) in ovarian cancers suggesting the existence of one or more important tumor suppressor genes (TSGs). The tissue inhibitor of metalloproteinase-3 (TIMP-3) is a plausible TSG candidate since it is often encompassed within these regions of LOH. TIMP-3 has not previously been investigated for somatic mutations or promoter hypermethylation in ovarian cancer. We analyzed 65 ovarian cancers for both somatic genetic mutations and TIMP-3 promoter hypermethylation. Screening of all coding exons of TIMP-3 did not reveal any somatic genetic mutations and only 1/65 showed TIMP-3 methylation. Our data indicate that inactivation of TIMP-3 by somatic mutation or promoter hypermethylation is rare in ovarian cancer.

References

Apr 1, 1994·Human Molecular Genetics·I G CampbellE Solomon
Feb 14, 1998·International Journal of Cancer. Journal International Du Cancer·F AllioneD Birnbaum
Aug 14, 1999·Journal of Neuropathology and Experimental Neurology·Y InoD N Louis
Jul 4, 2002·Methods : a Companion to Methods in Enzymology·Alexander DobrovicDamian Hussey
Sep 6, 2002·The American Journal of Pathology·Sun LeeGyeong Hoon Kang
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ralf KemkemerDieter Kaufmann
Mar 12, 2003·The Journal of Clinical Endocrinology and Metabolism·Anja WildDetlef K Bartsch
Jul 10, 2003·Cancer Genetics and Cytogenetics·M Eva AlonsoJuan A Rey
Sep 14, 2004·Oncogene·Kate D SutherlandJane E Visvader
Dec 4, 2004·Genes, Chromosomes & Cancer·Magdalena BenetkiewiczJan P Dumanski

❮ Previous
Next ❯

Citations

Oct 13, 2009·Experimental and Molecular Pathology·Jean-François GagnonCaroline Diorio
Mar 3, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Damien MassonMarc G Denis
Jul 23, 2011·Biomolecular Concepts·Andrei V Chernov, Alex Y Strongin
Jul 28, 2016·Journal of Cancer Research and Therapeutics·Hamed MirzaeiHamid Reza Mirzaei
Oct 10, 2006·Oncogene·T Dalmay, D R Edwards
Jul 31, 2019·Therapeutic Advances in Medical Oncology·Chun-Wen SuShun-Fa Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.